SCHEMBL16626549

SCHEMBL16626549

CNCc1cn(S(=O)(=O)c2ccc(Cl)c(Cl)c2Cl)c2cc(Nc3ccc(C)cc3F)ccc12

nearest known ligand 0.36

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.36
HTT P42858 2/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HTR6 P50406 5/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
P2RX7 Q99572 1/20 0.32
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16619382 0.99 TSHR (0.35) TSHRHTTMAPTSMN1; SMN2HTR6
SCHEMBL16626743 0.92 PTGES2 (0.37) HTR6PDE4APDE4BPDE4CPDE4D
Hydrochloric Acid SCHEMBL16618775 0.92 PTGES2 (0.36) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL16626747 0.90 HTR6 (0.41) HTR6PDE4APDE4BPDE4CPDE4D
Hydrochloric Acid SCHEMBL16618904 0.89 HTR6 (0.41) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL16626613 0.89 KLK7 (0.39) HTR6PDE4APDE4BPDE4CPDE4D
Hydrochloric Acid SCHEMBL16618964 0.88 KLK7 (0.38) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL16626618 0.87 HTR6 (0.44) HTTMAPTHTR6PDE4APDE4B
SCHEMBL16626768 0.87 HTR6 (0.43) TSHRHTTMAPTHTR6
Hydrochloric Acid SCHEMBL16619535 0.86 HTR6 (0.43) HTTMAPTHTR6PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI TSHR 1542/4885HTT 2200/4885MAPT 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.